NCT01047007 2023-09-21
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Merck Sharp & Dohme LLC
Phase 1 Terminated
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca